Torrent Pharmaceuticals’ US-based subsidiary -- Torrent Pharma Inc's has received warning letter from the US Food and Drug Administration (USFDA) for violations of good manufacturing practices, including lack of properly designed equipment and packing material. The plant's water system was not adequately designed, controlled, maintained, and monitored to ensure it consistently produced water that met specifications and appropriate microbial limits.
Torrent Pharmaceuticals is Flagship Company of the Torrent group, a leader in cardiovascular and central nervous system segments. It also has presence in gastro-intestinal, diabetology, anti-infective and pain management segments.
